The U.S. Food and Drug Administration has released draft guidance, which seeks to establish a framework for classifying significant postmarketing drug safety issues as priority, standard or emergency for timely resolution.
Read the full report in Becker's Hospital Review on the FDA's draft guidance.
Read the full report in Becker's Hospital Review on the FDA's draft guidance.
